IRIS
ROGLIANI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 71.818
EU - Europa 5.561
AS - Asia 3.873
SA - Sud America 66
OC - Oceania 30
Continente sconosciuto - Info sul continente non disponibili 22
AF - Africa 16
Totale 81.386
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 71.764
SG - Singapore 1.772
CN - Cina 1.122
IE - Irlanda 1.053
IT - Italia 914
UA - Ucraina 781
KR - Corea 742
DE - Germania 686
PL - Polonia 465
FR - Francia 435
RU - Federazione Russa 324
GB - Regno Unito 296
FI - Finlandia 212
SE - Svezia 205
CA - Canada 46
VN - Vietnam 42
JP - Giappone 38
NL - Olanda 36
BE - Belgio 35
IN - India 31
BR - Brasile 30
AU - Australia 25
ES - Italia 25
HK - Hong Kong 24
RO - Romania 16
CL - Cile 14
GR - Grecia 14
CZ - Repubblica Ceca 13
MY - Malesia 13
A2 - ???statistics.table.value.countryCode.A2??? 11
PT - Portogallo 11
TR - Turchia 11
EU - Europa 10
TW - Taiwan 9
EC - Ecuador 8
ID - Indonesia 8
AT - Austria 7
IL - Israele 7
KG - Kirghizistan 7
EG - Egitto 6
IR - Iran 6
CO - Colombia 5
HR - Croazia 5
MX - Messico 5
NZ - Nuova Zelanda 5
PE - Perù 5
PH - Filippine 5
AR - Argentina 4
CH - Svizzera 4
DK - Danimarca 4
IQ - Iraq 4
LY - Libia 4
BD - Bangladesh 3
JO - Giordania 3
KE - Kenya 3
KH - Cambogia 3
NP - Nepal 3
RS - Serbia 3
SA - Arabia Saudita 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
BG - Bulgaria 2
HU - Ungheria 2
IS - Islanda 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LT - Lituania 2
MK - Macedonia 2
MO - Macao, regione amministrativa speciale della Cina 2
NO - Norvegia 2
TH - Thailandia 2
ZA - Sudafrica 2
A1 - Anonimo 1
AM - Armenia 1
AZ - Azerbaigian 1
CR - Costa Rica 1
EE - Estonia 1
ET - Etiopia 1
GT - Guatemala 1
LB - Libano 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
NI - Nicaragua 1
PK - Pakistan 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 81.386
Salva come PNG Salva come JPEG
Città #
Wilmington 19.935
Houston 18.432
Woodbridge 18.204
Fairfield 2.959
Singapore 1.567
Ann Arbor 1.452
Chandler 1.247
Ashburn 1.226
Seattle 1.173
Cambridge 955
Dublin 900
Medford 683
Jacksonville 558
Dearborn 461
Kraków 456
Santa Clara 424
Beijing 361
New York 359
Rome 334
Lawrence 321
Zhengzhou 279
San Diego 173
Moscow 108
Menlo Park 106
Milan 81
Hangzhou 73
Shanghai 72
Redwood City 63
Norwalk 62
London 58
Palo Alto 46
Helsinki 43
Jinan 42
Nanjing 40
Mülheim 37
Dong Ket 35
Boardman 33
Brussels 33
Hefei 32
San Jose 30
Mountain View 28
Falls Church 27
Guangzhou 26
Verona 26
Kunming 25
La Veta 25
Phoenix 25
Chicago 23
Seoul 23
Detroit 21
Durham 21
Lappeenranta 20
Toronto 20
Los Angeles 19
San Francisco 19
Saint Petersburg 17
Kilburn 15
Nuremberg 15
Chengdu 14
Jiaxing 14
São Paulo 14
Parma 13
San Mateo 13
Wuhan 13
Munich 12
Nanchang 12
Naples 12
University Park 12
Prescot 11
Redmond 11
Council Bluffs 10
Hounslow 10
Washington 10
Brno 9
Kuala Lumpur 9
Stockholm 9
Central 8
Fuzhou 8
Hong Kong 8
Acton 7
Athens 7
Bari 7
Chiswick 7
Indianapolis 7
Melbourne 7
The Dalles 7
Tokyo 7
Canberra 6
Frankfurt am Main 6
Giv‘atayim 6
Iasi 6
Islington 6
Leeds 6
Palermo 6
Shenyang 6
Taipei 6
Wandsworth 6
Xi'an 6
Xian 6
Acerra 5
Totale 74.213
Salva come PNG Salva come JPEG
Nome #
An update on the pharmacotherapeutic management of lower respiratory tract infections 493
Feasibility and results of awake thoracoscopic resection of solitary pulmonary nodules 490
Vats lung reduction in patients with advanced emphysema 488
Thoracoscopic reduction pneumoplasty for severe emphysema: Do pleural adhesions affect outcome? 469
Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis 463
Asthma and COPD in an Italian adult population: Role of BMI considering the smoking habit 461
Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells 461
Awake thoracoscopic biopsy of interstitial lung disease 460
Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis 454
Effect of lung volume reduction surgery for severe emphysema on right ventricular function 452
Interaction between corticosteroids and muscarinic antagonists in human airways 452
Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma? 446
Completion lobectomy after bilateral lung volume reduction for emphysema: Salvage option or fancy? 443
Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation 439
An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network 436
Onset of action of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in patients with COPD 436
A 6MWT index to predict O2 flow correcting exercise induced SpO2 desaturation in ILD 435
Therapeutic novelties of inhaled corticosteroids and bronchodilators in asthma 431
Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. 428
Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab 428
Glucagon-like peptide 1 receptor: A novel pharmacological target for treating human bronchial hyperresponsiveness 427
Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases 426
Unilateral thoracoscopic reduction pneumoplasty for asymmetric emphysema 424
Minimalist video-assisted thoracic surgery biopsy of mediastinal tumors 423
Optimizing drug delivery in COPD: The role of inhaler devices 423
Withdrawal of inhaled corticosteroids in COPD: A meta-analysis 422
Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update 421
A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD 420
Treatment options for moderate-to-very severe chronic obstructive pulmonary disease 419
Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease 419
Asthma and comorbid medical illness. 418
Pharmacological treatments in asthma-affected horses: A pair-wise and network meta-analysis 417
Serum- and Glucocorticoid-Inducible Kinase 1 Delay the Onset of Endothelial Senescence by Directly Interacting with Human Telomerase Reverse Transcriptase 416
Tiotropium formulations and safety: a network meta-analysis 416
LABA/LAMA combination in copd: A meta-analysis on the duration of treatment 416
Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis 415
Airflow obstruction: Is it asthma or is it COPD? 414
Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease 413
Can a better patients' phenotyping predict the efficacy of tiotropium in symptomatic asthma? 413
Can pet keeping be considered the only criterion of exposure to cat/dog allergens in the first year of life? 412
Can a better patient phenotyping predict the efficacy of tiotropium in asthmatic adolescents? 411
High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. 409
How many systemic reactions to skin prick tests could be preventable in defined conditions? 408
Occupational allergy to horse allergens: More than exposure to horses! 407
Is H1-antihistamine (desloratadine 5 mg, orodispersible tablet) premedication in NSAID-associated urticaria really safe and practicable in “real life”? 407
Is allergic sensitization to siberian hamster preventable in high-risk individuals who are already sensitized or exposed to furry animals? 406
Role of muscarinic antagonists in asthma therapy 404
Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease 404
Asthma and comorbid medical illness 403
Randomized comparison of awake nonresectional versus nonawake resectional lung volume reduction surgery. 403
Occupational allergy to horse allergens: More than exposure to horses! 402
Bronchodilator therapy for chronic cough 402
Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298 401
Feasibility and results of awake thoracoscopic resection of solitary pulmonary nodules 401
Completion lobectomy after bilateral lung volume reduction for emphysema: salvage option or fancy? 401
Combined pulmonary fibrosis and emphysema: 3D time-resolved MR angiographic evaluation of pulmonary arterial mean transit time and time to peak enhancement 397
The role of epsilon PKC in acute and chronic diseases: Possible pharmacological implications of its modulators 397
Role of the HLA-DP Glu 69 and the TNF-alpha TNF-alpha 2 gene markers in susceptibility to beryllium hypersensitivity 396
Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways 396
Dog allergen immunotherapy and allergy to furry animals 396
Asthma management in a specialist setting: Results of an Italian Respiratory Society survey 396
QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease 393
Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi 392
Results of unilateral lung volume reduction surgery in patients with distinct heterogeneity of emphysema between lungs 391
Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: A point of view 390
Metabolic syndrome and risk of pulmonary involvement 390
Epithelial-smooth muscle cooperation is needed for brain natriuretic peptide-dependent bronchorelaxant activity. 390
The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils 389
The Challenges of Precision Medicine in COPD 389
HRCT and histopathological evaluation of fibrosis and tissue destruction in IPF associated with pulmonary emphysema 388
Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease 388
Can the presence of cat/dog at home be considered the only criterion of exposure to cat/dog allergens? A likely underestimated bias in clinical practice and in large epidemiological studies 388
New Treatments for COPD in the Elderly 387
Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study 386
Clinical effect of corticosteroids in asthma-affected horses: A quantitative synthesis 385
The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease 384
Umeclidinium for the treatment of chronic obstructive pulmonary disease 383
Clinical features and outcome of hospitalized patients with HSV-1 DNA in the lower respiratory tract 383
Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. 382
Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi 382
An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? 382
The effect of indacaterol during an acute exacerbation of COPD 380
Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study 379
Letter to the Editor: Can dog allergen immunotherapy reduce concomitant allergic sensitization to other furry animals? A preliminary experience 378
Assessment of pet exposure by questionnaires in epidemiological studies (but also in clinical practice!): Why the questions should be simplified? 377
Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome? 375
Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi 375
Impact of pulmonary vascular volume on mortality in IPF: Is it time to reconsider the role of vasculature in disease pathogenesis and progression? 375
Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone 374
Translational study searching for synergy between glycopyrronium and indacaterol 374
Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008 373
Chronic treatment with indacaterol and airway response to salbutamol in stable COPD 372
Comorbidities of asthma 372
HLA-DP-unrestricted TNF-alpha release in beryllium-stimulated peripheral blood mononuclear cells 372
Urgent awake thoracoscopic treatment of retained haemothorax associated with respiratory failure 372
Is the risk of developing atopic sensitization and bronchial asthma in animal laboratory workers preventable in well-defined susceptible individuals? 371
Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD 370
Biomarkers of lung damage associated with tobacco smoke in induced sputum 370
Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients 370
Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi 369
Totale 40.726
Salva come PNG Salva come JPEG
Categoria #
all - tutte 186.840
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 186.840
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202018.289 0 0 0 2.389 2.256 2.548 2.110 2.160 2.138 1.787 1.395 1.506
2020/202113.581 1.435 1.552 1.496 1.545 1.381 1.405 2.056 1.300 353 361 485 212
2021/20223.251 200 278 87 72 105 323 424 149 182 304 280 847
2022/20233.580 469 253 122 398 280 912 325 209 320 36 164 92
2023/20241.831 362 47 133 38 129 392 110 213 64 71 36 236
2024/20253.475 307 1.989 1.004 175 0 0 0 0 0 0 0 0
Totale 82.704